BioVaria 2025

BioVaria 2025

ABOUT BIOVARIA

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe.

This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of the global biotech and pharma industry.

//

  • Scientists, technology transfer professionals, investors and industry scouts
  • European technology transfer organizations presenting commercially attractive licensable technologies and partnership opportunities
  • Startup Pitch & Partner featuring some of Europe’s most promising startups
  • Face-to-face discussions with investors and inventors

STARTUP PITCH & PARTNER

The interactive BioVaria Startup Pitch & Partner Programme offers start-ups from all life-science areas (pharma, diagnostics, medtech and digital health)

  • the possibility to present their technology and business concept
  • direct exchange with potential VCs and investors during speed dating
  • the opportunity to network with representatives of the industry and the life science scene

Applications are open to pre- and post-seed start-ups. Start-ups selected by an expert jury of investors will then compete live on the BioVaria stage for a “BioVaria Startup Award” worth up to 2,000 euros.

The application deadline for start-ups is February 14, 2025.

The application form can be found on our website: https://www.biovaria.org/startup-pitch-partner/startup-pitch-partner

register now

Our latest News

discover more
Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Julian Friedrich from the DKFZ, HI-STEM* and Heidelberg University Hospital (UKHD) was included in the renowned Forbes ‘30 Under 30 Europe’ list in the Science & Healthcare category. The physician and cancer researcher, who has headed the Haematology and Immune Engineering junior research group since this year, initially developed successful approaches to reactivate the […]

Biotechnologie-Branche tagt im Life Science Hot Spot Heidelberg

Biotechnologie-Branche tagt im Life Science Hot Spot Heidelberg

Heidelberg 9. April 2025: Mehr als 1000 Teilnehmerinnen und Teilnehmer aus dem Biotech-Sektor sind heute in Heidelberg zu ihrer jährlichen Konferenz, den Deutschen Biotechnologietagen, eingetroffen. Unternehmerinnen und Unternehmer, Wissenschaftler sowie Vertreterinnen und Vertreter aus Politik, Administration und Medien tauschen sich hier für zwei Tage über die neuesten Entwicklungen in der Branche und die Rahmenbedingungen für […]

Epidemiological study shows: Vaccination against shingles could reduce the risk of developing dementia – especially in women!

Epidemiological study shows: Vaccination against shingles could reduce the risk of developing dementia – especially in women!

Scientists from the Faculty of Medicine at Heidelberg University, the University of Mainz, the SAFE Leibniz Institute Frankfurt, the Vienna University of Economics and Business, and Stanford University, USA, have examined Welsh health data on older people. They found that over a seven-year follow-up period, people who received the shingles vaccine were 20% less likely […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp